Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM2 | P50570 | 3/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21016702 | 0.76 | JAK3 (0.38) | JAK3CYP1A2CYP2D6ALDH1A1CYP3A4 | |
| SCHEMBL21091671 | 0.75 | CNR2 (0.34) | DNM2CYP1A2CYP2D6ALDH1A1CYP3A4 | |
| SCHEMBL20122627 | 0.71 | DNM2 (0.34) | DNM2CYP1A2CYP2D6ALDH1A1CYP3A4 | |
| SCHEMBL21016705 | 0.70 | DNM2 (0.50) | DNM2JAK3CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL20620243 | 0.66 | NPC1 (0.40) | CYP1A2ALDH1A1CYP2C19HSD17B10 | |
| SCHEMBL23720420 | 0.66 | ALOX12 (0.48) | CACNA2D1CYP2C19 | |
| SCHEMBL19352969 | 0.66 | ALOX12 (0.48) | CACNA2D1CYP2C19 | |
| SCHEMBL23768081 | 0.65 | DNM2 (0.36) | DNM2 | |
| SCHEMBL10444895 | 0.65 | KMT2A (0.36) | CYP1A2CYP2C19 | |
| SCHEMBL23768196 | 0.64 | ALDH1A1 (0.34) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253554-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253554-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | TYK2, JAK3, JAK2 | DNM2 1730/4885JAK3 2/4885CACNA2D1 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.